Quince Therapeutics, Inc., formerly Cortexyme, Inc., a biopharmaceutical company advancing precision therapeutics targeting debilitating and rare diseases, as part of its strategic growth plan, has changed it name and shifted its focus to prioritize the clinical development of its highly differentiated bone-targeting drug platform and lead precision bone growth molecule, NOV004, to address major, unmet medical needs across multiple skeletal therapeutic indications. Quince also plans to pursue th...